CALGB 40603 (Alliance): Long-Term Outcomes and Genomic
2022年4月20日 · Purpose: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by …
研究结果阴性，为啥治疗方案却被PI“强推”？ - 腾讯网
2022年2月11日 · calgb 40603是一项2×2随机ii期临床试验，结果显示，在每周一次紫杉醇治疗（wp）基础上加用卡铂或贝伐珠单抗，随后加用多柔比星和环磷酰胺可显著 ...
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic …
2022年1月19日 · CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and …
Prognostic and molecular multi-platform analysis of CALGB 40603 ...
2025年3月8日 · CALGB 40603 is a 2 × 2 factorial, randomized phase II trial that evaluated the impact of adding carboplatin and/or bevacizumab to standard chemotherapy.
Impact of the addition of carboplatin and/or bevacizumab to ... - PubMed
2015年1月1日 · Purpose: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). …
PURPOSE CALGB 40603 (NCT00861705), a 2 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and …
<br>CALGB 40603（联盟）：三阴性乳腺癌新辅助化疗联合或不 …
CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and …
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic …
2022年1月19日 · PURPOSE CALGB 40603 ( NCT00861705 ), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by …
J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不 …
2022年1月26日 · 近期，Journal of Clinical Oncology杂志上发表了II期临床研究CALGB 40603 (NCT00861705)的长期生存预后成果。 其目的是研究在每周紫杉醇(wP)联合AC (阿霉素和环 …
calgb-40603: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in